Serial No. 10/645,784

## RECEIVED CENTRAL FAX CENTER

JUN 0 3 2008

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-28. (Canceled).

 (Previously Presented). The process of Claim 46, wherein the gene construct is expressed in an E. coli cell.

30-45. (Canceled).

- 46. (Amended). A process for preparing a pharmacologically active compound, which comprises:
  - (a) selecting from a peptide phage display library at least one nucleic acid sequence encoding a peptide that modulates the activity of AGP-3, wherein "peptide" refers to molecules of 2 to 40 amino acids;
  - (b) preparing a gene construct that <u>encodes comprises</u> at least one said selected <u>peptide</u> sequence and an Fc domain;
  - (c) expressing a pharmacologically active compound from the gene construct, wherein the gene construct encodes a compound of the formula

$$(X^1)_a - F^1 - (X^2)_b$$

and multimers thereof, wherein:

F1 is an Fc domain;

 $X^1$  and  $X^2$  are each independently selected from  $-(L^1)_c - P^1$ ,  $-(L^1)_c - P^1 - (L^2)_d - P^1$ 

 $P^{2}, -(L^{1})_{c} - P^{1} - (L^{2})_{d} - P^{2} - (L^{3})_{e} - P^{3}, \text{ and } -(L^{1})_{c} - P^{1} - (L^{2})_{d} - P^{2} - (L^{3})_{e} - P^{3} - (L^{4})_{r} - P^{4}$ 

P<sup>1</sup>, P<sup>2</sup>, P<sup>3</sup>, and P<sup>4</sup> are each independently encoded by the selected peptide sequences;

 $L^1$ ,  $L^2$ ,  $L^3$ , and  $L^4$  are each independently linkers; and

- a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1
- (c) expressing the pharmacologically active compound comprising the Fcpeptide fusion protein from said gene construct; and
- (d) <u>Isolating said expressed protein</u>, wherein said isolated protein modulates the <u>activity of AGP-3</u>.

Serial No. 10/645,784

47. (Original). The process of Claim 46, wherein the compound prepared is of the formulae  $X^1$ - $F^1$ 

or

 $F^1-X^2$ .

48. (Original). The process of Claim 46, wherein the compound prepared is of the formulae  $F^1-(L^1)_c-P^1$ 

or

$$F^{1}$$
-( $L^{1}$ )<sub>c</sub>- $P^{1}$ -( $L^{2}$ )<sub>d</sub>- $P^{2}$ .

- 49. (Original). The process of Claim 46, wherein F<sup>1</sup> is an IgG Fc domain.
- 50. (Original). The process of Claim 46, wherein F<sup>1</sup> is an IgG1 Fc domain.
- 51. (Original). The process of Claim 46, wherein F<sup>1</sup> comprises the sequence of SEQ ID NO: 2.

Claims 52-62 (Canceled).

- 63. (Previously Presented). The process of Claim 46 wherein a is 1 and b is 0.
- 64. (Previously Presented). The process of Claim 46 wherein  $X^1$  is  $-(L^1)_c P^1 (L^2)_d P^2$ .
- 65. (Previously Presented). The process of Claim 63 wherein X<sup>1</sup> is -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>.
- 66. (Previously Presented). The process of Claim 65 wherein L<sup>1</sup> is (Gly)<sub>5</sub>.
- 67. (Previously Presented). The process of Claim 65 wherein L2 is (Gly)5.
- 68. (Previously Presented). The process of Claim 66 wherein L2 is (Gly)5.
- 69-79. (Canceled).